17,554) (58,311)
- depreciation of property, plant
and equipment and amortization of
licenses and permits 891,007 483,670
- deferred government grant
recognized in income (65,830) (51,316)
- accounts receivable 1,829,731 (2,462,999)
- inventories (3,771,749) (2,331,763)
- income tax payable (2,628,408) (885,252)
- prepaid expenses and deposits (335,770) 30,904
- long term payable, deferred
revenue and advances from customers (234,054) --
- accounts payable and accrued
liabilities (6,100,581) (2,771,775)
Net cash used in operating activities (10,146,421) (6,832,231)
Cash flows from (used in) financing
activities
- Loan proceeds 8,265,031 --
- Proceeds from issuance of common
stock net of share issuance costs 61,867,706 --
- Repurchase of common shares -- (319,643)
- Loan to non-controlling
shareholder of Sinovac Beijing (6,572,159) (1,460,600)
- Government grant received 46,811 --
Net cash provided by (used in)
financing activities 63,607,389 (1,780,243)
Cash flows used in investing
activities
- Restricted cash 57,961 --
- Proceeds from disposal of
equipment 189,876 --
- Proceeds from redemption of short -
term investments 7,314,187 --
- Purchase of short-term investments (8,338,173) --
- Pr
'/>"/>SOURCE Sinovac Biotech Ltd. Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Related biology technology :1.
Sinovac to Host Conference Call to Report First Quarter 2010 Financial Results2.
Sinovac Announces Upsizing and Pricing of Common Share Offering3.
Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease4.
Sinovacs CEO Weidong Yin Presented with Annual Innovation Award by China Central Television5.
Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities6.
Sinovac Reports Unaudited Third Quarter 2009 Financial Results7.
Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government8.
Sinovac Receives Certificate of Approval to Distribute Panflu (H5N1) Vaccine in Hong Kong9.
Sinovac to Present at 2009 UBS Global Life Sciences Conference10.
Sinovac Obtains Lot Release Certificate for Its First Batch of H1N1 Vaccine11.
Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government